Clinical trial
Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients…
NCT00156286 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00156286 |
|---|---|
| Title | Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC |
| Official title | Phase II Trial of Gleevec (Imatinib Mesylate, STI571) Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive, Extensive-Stage Small Cell Lung Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Gleevec |
| Enrollment | 20 |
| Start date | Mar 1, 2002 |
| Primary completion | Jan 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 16, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: